DayOne Data Centers, based in Singapore, jumped into the US IPO queue with a filing that could shake up the digital infrastructure landscape. On October 5, 2026, the company submitted paperwork to the US Securities and Exchange Commission, aiming to list American depositary shares on Nasdaq under the ticker DODC. The registration statement points to a possible $3 billion raise and a $20 billion valuation, but the final deal size and price band remain open. The SEC has not yet declared the registration effective, according to a Reuters financial review.
Morgan Stanley and J.P. Morgan are leading the underwriter group, joined by BofA Securities and Citigroup. DayOne’s timing lands in the middle of choppy waters for AI infrastructure, where market swings can upend IPO pricing and investor appetite overnight.
In the first half of 2026, DayOne Data Centers reported revenue of $512 million but posted a net loss of $81.9 million, a significant increase from the previous year’s $151.5 million in revenue and $13.5 million net loss.
While DayOne’s ambitions draw attention, biotech IPOs are running into headwinds. TRex Bio, which targets autoimmune diseases, priced its deal at the bottom of the range and raised $117 million for a $422 million market cap. The company’s Deep Biology platform tracks regulatory T cell activity in human tissue to pinpoint drug targets. Its lead asset, TRB-061, is a TNFR2 agonist now in a Phase 1b trial for moderate-to-severe atopic dermatitis. Topline results are not due until mid-2027. TRex Bio’s shares closed the week unchanged, a sign that investors remain wary of early-stage clinical bets.
Retension Pharmaceuticals, focused on hypertension, managed to boost its IPO size and price at the midpoint, pulling in $45 million for a $114 million valuation. Its only drug, RTN-001, is a once-daily oral PDE-5 inhibitor licensed in and now in a Phase 2b dose-ranging trial for uncontrolled and resistant hypertension. Initial data are expected in the first half of 2027. Even with the bigger raise, Retension’s shares dropped 12% by week’s end, showing that skepticism around single-asset, mid-stage biotech remains stubborn.
Elsewhere in the IPO pipeline, an emerging markets fintech and a dental treatment company filed to go public. Still, DayOne Data Centers’ blockbuster filing keeps the spotlight on digital infrastructure. The company’s move comes as AI infrastructure valuations swing wildly, rattling confidence and forcing other IPO hopefuls to rethink their plans. Recent market shifts are detailed in our earlier breakdown.
In February 2026, DayOne was reportedly considering raising up to $5 billion at a potential $20 billion valuation, but the current F-1 filing does not confirm a final deal size, and the $3 billion figure remains provisional.
IPO indices are showing momentum. As of October 8, 2026, the Renaissance IPO Index had climbed 16.3% for the year, beating the S&P 500’s 14.4% gain. The Renaissance International IPO Index posted a 24.0% jump, compared to the ACWX’s 13.1%. Top ETF holdings include Astera Labs and SpaceX, along with Galderma and Kioxia, marking a shift toward technology and infrastructure listings.
DayOne Data Centers is chasing a multibillion-dollar raise as biotech IPOs deliver uneven outcomes. Investors are rewarding companies with strong platforms and clear clinical or commercial milestones, while punishing those seen as risky or dependent on a single asset. The next wave of listings will show whether digital infrastructure giants can lock in premium valuations in a volatile market.
